Publications by authors named "H F Hashmi"
Idecabtagene vicleucel (ide-cel) is an anti-BCMA CAR-T cell therapy approved for patients with relapsed/refractory multiple myeloma (RRMM) after 2 prior lines of therapy. There is limited data on outcomes of CAR T in older adults and frail patients with RRMM. In this study, we utilized data from the Center for International Blood and Marrow Transplantation Registry to describe the safety and efficacy of ide-cel in these clinically important subgroups.
View Article and Find Full Text PDFObjective: Healthcare workers are at a higher risk of burnout. The aim of the study was to explore the professional quality of life (QOL) i.e.
View Article and Find Full Text PDFArticle Synopsis
- CAR T-cell therapy shows strong initial results for treating relapsed refractory multiple myeloma, but most patients eventually relapse, often within 5 months.
- In a study of 139 patients who relapsed after CAR T-cell therapy, different salvage therapies were analyzed, revealing that bispecific antibodies, like talquetamab and teclistamab, had the best overall and complete response rates.
- The presence of extramedullary disease at relapse was linked to poorer outcomes, but bispecific antibodies improved survival rates, suggesting they should be the standard treatment for patients relapsing after CAR T-cell therapy.
Background: The efficacy of elotuzumab, an anti-SLAMF7 monoclonal antibody, in treating relapsed/refractory multiple myeloma (RRMM) and newly-diagnosed multiple myeloma (NDMM) has varied in randomized controlled trials (RCTs). Moreover, there is limited data on its real-world application.
Patients And Methods: We conducted a systematic review and meta-analysis of RCTs investigating the addition of elotuzumab to backbone antimyeloma regimens.
Article Synopsis
- Clinical trials on CAR T-cell therapy for relapsed/refractory multiple myeloma usually exclude patients with AL amyloidosis, leading to a lack of data on its effectiveness for this group.
- A study reviewed eight patients with both RRMM and AL amyloidosis who underwent standard CAR T-cell therapy, revealing that 75% experienced cytokine release syndrome and low-grade cytopenias were common.
- The therapy resulted in rapid and significant responses, with a median time to best response of 43 days and a 62.5% rate of achieving a very good partial response or better, indicating that CAR T-cell therapy is feasible and effective for these patients.